Cargando…
Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
In clinical trials of tofacitinib for rheumatoid arthritis (RA), Japanese and Korean patients had higher incidence of herpes zoster (HZ) than subjects from elsewhere; however, post-market data from Asia are lacking. Hence, we investigated the incidence of HZ and its risk factors in Taiwanese RA pati...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544164/ https://www.ncbi.nlm.nih.gov/pubmed/33031288 http://dx.doi.org/10.1097/MD.0000000000022504 |
_version_ | 1783591802984464384 |
---|---|
author | Chen, Yen-Ju Chen, Yi-Ming Huang, Wen-Nan Chen, Hsin-Hua Liao, Tsai-Ling Chen, Jun-Peng Hsieh, Tsu-Yi Chen, Yi-Hsing Chen, Der-Yuan |
author_facet | Chen, Yen-Ju Chen, Yi-Ming Huang, Wen-Nan Chen, Hsin-Hua Liao, Tsai-Ling Chen, Jun-Peng Hsieh, Tsu-Yi Chen, Yi-Hsing Chen, Der-Yuan |
author_sort | Chen, Yen-Ju |
collection | PubMed |
description | In clinical trials of tofacitinib for rheumatoid arthritis (RA), Japanese and Korean patients had higher incidence of herpes zoster (HZ) than subjects from elsewhere; however, post-market data from Asia are lacking. Hence, we investigated the incidence of HZ and its risk factors in Taiwanese RA patients receiving tofacitinib. At a medical center in Taichung, Taiwan, we enrolled patients with active RA treated with tofacitinib between January 4, 2015 and December 9, 2017, following unsuccessful methotrexate therapy and no tofacitinib exposure RA patients as a control group. Demographic characteristics, interferon-gamma levels, and lymphocyte counts were compared. Among 125 tofacitinib-treated RA patients, 7 developed HZ, an incidence rate of 3.6/100 person-years. Patients with HZ had shorter disease duration than those without, but higher frequency of prior HZ. Baseline interferon-gamma levels and HLA-DR(+) activated T cell counts were positively correlated and significantly lower in patients with HZ than without. Strikingly, 5/7 HZ cases occurred within 4 months of starting tofacitinib therapy. Incidence of HZ in tofacitinib-treated Taiwanese RA patients is lower than rates in Japan or Korea, and commensurate with the global average. HZ may occur soon after commencing tofacitinib therapy. The role of interferon-gamma and activated T cells in tofacitinib-related HZ deserves further investigation. |
format | Online Article Text |
id | pubmed-7544164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75441642020-10-30 Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan Chen, Yen-Ju Chen, Yi-Ming Huang, Wen-Nan Chen, Hsin-Hua Liao, Tsai-Ling Chen, Jun-Peng Hsieh, Tsu-Yi Chen, Yi-Hsing Chen, Der-Yuan Medicine (Baltimore) 6900 In clinical trials of tofacitinib for rheumatoid arthritis (RA), Japanese and Korean patients had higher incidence of herpes zoster (HZ) than subjects from elsewhere; however, post-market data from Asia are lacking. Hence, we investigated the incidence of HZ and its risk factors in Taiwanese RA patients receiving tofacitinib. At a medical center in Taichung, Taiwan, we enrolled patients with active RA treated with tofacitinib between January 4, 2015 and December 9, 2017, following unsuccessful methotrexate therapy and no tofacitinib exposure RA patients as a control group. Demographic characteristics, interferon-gamma levels, and lymphocyte counts were compared. Among 125 tofacitinib-treated RA patients, 7 developed HZ, an incidence rate of 3.6/100 person-years. Patients with HZ had shorter disease duration than those without, but higher frequency of prior HZ. Baseline interferon-gamma levels and HLA-DR(+) activated T cell counts were positively correlated and significantly lower in patients with HZ than without. Strikingly, 5/7 HZ cases occurred within 4 months of starting tofacitinib therapy. Incidence of HZ in tofacitinib-treated Taiwanese RA patients is lower than rates in Japan or Korea, and commensurate with the global average. HZ may occur soon after commencing tofacitinib therapy. The role of interferon-gamma and activated T cells in tofacitinib-related HZ deserves further investigation. Lippincott Williams & Wilkins 2020-10-09 /pmc/articles/PMC7544164/ /pubmed/33031288 http://dx.doi.org/10.1097/MD.0000000000022504 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 6900 Chen, Yen-Ju Chen, Yi-Ming Huang, Wen-Nan Chen, Hsin-Hua Liao, Tsai-Ling Chen, Jun-Peng Hsieh, Tsu-Yi Chen, Yi-Hsing Chen, Der-Yuan Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan |
title | Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan |
title_full | Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan |
title_fullStr | Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan |
title_full_unstemmed | Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan |
title_short | Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan |
title_sort | herpes zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from taiwan |
topic | 6900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544164/ https://www.ncbi.nlm.nih.gov/pubmed/33031288 http://dx.doi.org/10.1097/MD.0000000000022504 |
work_keys_str_mv | AT chenyenju herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT chenyiming herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT huangwennan herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT chenhsinhua herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT liaotsailing herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT chenjunpeng herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT hsiehtsuyi herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT chenyihsing herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan AT chenderyuan herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan |